Larvol Delta - Biodexa-Announces-Approval-of-CTA-in-Europe-for-Phase-3-Serenta-Trial-in-FAP-First-European-patient-expected-to-be-enrolled-in-4Q-2025-Addressable-US--European-Market-Put-at-7-Billion

eRapa (encapsulated rapamycin) - Biodexa Pharma

https://www.globenewswire.com/news-release/2025/11/03/3179260/0/en/Biodexa-Announces-Approval-of-CTA-in-Europe-for-Phase-3-Serenta-Trial-in-FAP-First-European-patient-expected-to-be-enrolled-in-4Q-2025-Addressable-US-European-Market-Put-at-7-Billi.html

Nov 3, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next